Mdr1 mRNA expression differs between grade III astrocytomas and glioblastomas

Area of Science:

• Neuro-oncology
• Molecular Biology
• Cancer Research

Background:

• P-glycoprotein (mdr1) is a drug efflux pump implicated in multidrug resistance in cancer.
• Understanding mdr1 expression in astrocytic tumors is crucial for predicting treatment response.

Purpose of the Study:

• To analyze the expression of mdr1 transcripts in untreated astrocytic tumors.
• To investigate the correlation between mdr1 expression, tumor grade, and histological subtype.

Main Methods:

• Quantitative analysis of mdr1 transcript expression using RT-PCR on 104 frozen samples from 33 astrocytic tumors.
• Utilized beta2-microglobulin as an internal control for gene expression analysis.
• Compared mdr1 expression levels between anaplastic astrocytomas (Grade 3) and glioblastomas (Grade 4).

Main Results:

• Significant inter- and intra-tumoral variation in mdr1 expression was observed in 50% of cases.
• Grade 3 astrocytomas showed significantly lower mdr1 expression (78% with minimal expression) compared to glioblastomas (23% with minimal expression).
• No significant differences in mdr1 expression were found when selecting samples with the highest expression, suggesting potential confounding factors like capillary mRNA contribution.

Conclusions:

• Mdr1 expression levels differ between astrocytic tumor grades, with lower expression in higher-grade tumors.
• The findings support a correlation between tumor grade and reduced mdr1 expression in certain astrocytic tumors.
• In vitro studies indicated no induction of mdr1 in response to common glioma chemotherapeutic agents (ACNU, VM26).